Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide cardiovascular safety study in adults with overweight or obesity
2022-502442-27-00Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Peptides
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Survodutide with Placebo (2 arms). Primary endpoint: Time to first 5-point major adverse cardiovascular event. Started Dec 2023; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2022-502442-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502442-27-00.